The present invention relates to novel pyrimidones of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly novel pyrimidones of the general formula (I).
1
The present invention relates to novel pyrimidones of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly novel pyrimidones of the general formula (I)
A series of N1-(substituted phenyl) pyridinecarboxamidines was synthesized by the condensation of substituted anilines with cyanopyridines in the presence of aluminum chloride or sodium amide and these compounds were evaluated for antiinflammatory activity by the carrageenin-induced rat paw edema assay. In the synthesis of N1-alkoxyphenyl pyridinecarboxamidines, it was found that o-alkoxyanilines reacted with aluminum chloride to afford o-aminophenol, while m- and p-alkoxyanilines were scarcely dealkylated. Sodium amide was successfully used for the condensation of o-alkoxyanilines with cyanopyridines. Among several active derivatives, N1-(2, 4-dichlorophenyl) pyridinecarboxamidine and N1-(4-chlorophenyl)-pyridinecarboxamidine exhibited significant antiinflammatory activities.